Integra LifeSciences (NASDAQ:IART) Releases FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $2.41 to $2.51 for the period, compared to the consensus EPS estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Ratings Changes

IART has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Citigroup increased their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Price Performance

NASDAQ IART traded up $3.12 on Tuesday, hitting $25.17. The stock had a trading volume of 473,108 shares, compared to its average volume of 558,733. The firm has a 50-day moving average of $23.68 and a 200-day moving average of $21.81. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -277.74, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $44.91.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.11. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same quarter last year, the business posted $0.89 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. Equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.